Welcome to our dedicated page for Outlook Therapeutics SEC filings (Ticker: OTLK), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Outlook Therapeutics, Inc. (OTLK) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Outlook Therapeutics is a biopharmaceutical company focused on ONS-5010/LYTENAVA™ (bevacizumab-vikg, bevacizumab gamma), an ophthalmic formulation of bevacizumab for retina diseases such as wet AMD, and its filings give detailed insight into how this program is progressing through clinical, regulatory, and commercial stages.
Form 8-K current reports are particularly important for OTLK, as they document material events such as the resubmission of the Biologics License Application (BLA) for ONS-5010, FDA classification of the resubmission as a Class 1 review with an associated PDUFA goal date, and the completion of a Type A meeting to discuss a complete response letter (CRL). Other 8-K filings cover executive appointments and departures, stock option inducement grants, and the release of quarterly and annual financial results.
Investors can also use SEC filings to track Outlook Therapeutics’ listing details on The Nasdaq Stock Market LLC under the symbol OTLK, as well as to review risk factor discussions, financial condition, and updates on the NORSE clinical trial program and commercial launch activities referenced in periodic reports. These documents complement the company’s press releases by providing formal, structured descriptions of key events and agreements.
On Stock Titan, Outlook Therapeutics filings are updated as they are made available on EDGAR. AI-powered tools summarize lengthy disclosures, highlight the main points from forms such as 8-Ks and periodic reports, and make it easier to understand technical language around FDA interactions, clinical data references, and compensation arrangements. This allows readers to quickly grasp what each filing means for ONS-5010/LYTENAVA™, the company’s regulatory pathway, and its overall corporate developments.
Outlook Therapeutics, Inc. Schedule 13G discloses that Mitchell P. Kopin, Daniel B. Asher and Intracoastal Capital LLC (the Reporting Persons) are filing jointly to report beneficial ownership tied to a Securities Purchase Agreement dated April 22, 2026. The Reporting Persons may be deemed to beneficially own 5,990,447 shares of Common Stock, representing 4.99% of the class based on 103,067,190 shares outstanding (prior to the SPA). The filing describes additional shares issuable upon exercise of warrants (including 6,451,613 shares under Intracoastal Warrant 1 and warrants totaling 2,000,000 or adjusted figures subject to blocker provisions) and explains blocker provisions that prevent exercises that would push ownership above 4.99%.
Outlook Therapeutics, Inc. entered into a registered direct offering and concurrent private placement, issuing 16,129,033 shares of common stock and matching common warrants at a combined price of $0.31 per share and warrant, for gross proceeds of about $5.0 million before fees.
The warrants carry a $0.31 exercise price, become exercisable after stockholder approval and an increase in authorized shares, and have a five‑year term from the later of that date and the effectiveness of a resale registration statement. The company also issued placement agent warrants and agreed to standard cash fees, and separately amended 2,142,854 existing warrants to reduce their exercise price to $0.31 and extend their life to five years after future stockholder approval. Net proceeds are planned primarily for working capital and general corporate purposes.
Outlook Therapeutics, Inc. is offering 16,129,033 shares of common stock at $0.31 per share in a registered offering, with gross proceeds of $5.0 million and estimated net proceeds to the company of approximately $4.2 million. The offering includes a concurrent private placement of detachable warrants to purchase up to 16,129,033 shares at a $0.31 exercise price; those warrants are unregistered and become exercisable only after stockholder approval and an amendment to increase authorized shares. Shares outstanding after this offering are expected to be 120,743,252, based on 104,614,219 shares outstanding as of March 31, 2026. The company reported $8.7 million in cash and cash equivalents as of December 31, 2025 and estimates that available funds, including recent financings, fund operations into August 2026. The company discloses multiple FDA Complete Response Letters for ONS-5010/LYTENAVA and substantial doubt about its ability to continue as a going concern.
Outlook Therapeutics filed an 8-K after completing a Federal Dispute Resolution meeting with the FDA’s Office of New Drugs regarding ONS-5010/LYTENAVA, its investigational bevacizumab formulation for wet age-related macular degeneration in the United States. The company expects a formal FDA decision from this dispute process in May 2026 and plans to update the market after receiving the agency’s response.
LYTENAVA already holds centralized Marketing Authorization in the European Union and separate authorization in the UK for wet AMD, and commercial launch has begun in Germany and the UK. In the United States, the product remains investigational following a December 30, 2025 Complete Response Letter on its biologics license application.
Outlook Therapeutics filed a report describing a key regulatory step for its retina drug candidate ONS-5010/LYTENAVA™ (bevacizumab‑vikg) in the United States. After receiving a Complete Response Letter from the FDA on December 30, 2025 for its Biologics License Application in neovascular age‑related macular degeneration, the company submitted a formal dispute resolution request. The FDA has accepted this request and granted a meeting with the deciding official in April 2026, giving the company an opportunity to argue that Phase 3 NORSE TWO and additional NORSE EIGHT data sufficiently support approval. The company notes that no safety concerns have been raised by the FDA and highlights that LYTENAVA already holds Marketing Authorizations in the EU and UK for wet AMD, where commercial launch has begun.
Outlook Therapeutics completed a best-efforts public offering of common stock and warrants. The company sold 20,000,000 shares of common stock with accompanying warrants to purchase up to 20,000,000 shares at a combined public price of $0.25 per share-and-warrant.
Gross proceeds were approximately $5.0 million, with net proceeds of about $4.0 million after placement agent fees and expenses. The investor warrants are exercisable immediately at $0.25 per share and expire five years from issuance, subject to 4.99% or 9.99% beneficial ownership caps.
H.C. Wainwright & Co. received cash fees and 1,400,000 placement agent warrants exercisable at $0.3125 per share, also for five years. The company agreed to certain lock-up and no variable-rate issuance covenants, and used an existing Form S-3 shelf registration and prospectus supplement for this transaction.
Outlook Therapeutics, Inc. is offering 20,000,000 shares of common stock together with warrants to purchase up to 20,000,000 shares, at a combined public offering price of $0.25 per share and accompanying warrant. The offering includes placement agent warrants to purchase 1,400,000 shares (7.0% of shares sold) exercisable at $0.3125. Delivery of securities is expected on or about March 25, 2026.
The prospectus supplement states net proceeds to the company from a full subscription would be approximately $4.0 million after placement agent fees and estimated expenses, but this is a best-efforts offering with no minimum amount required to close. The company reported 84,614,219 shares outstanding as of March 20, 2026 and discloses substantial liquidity needs, existing convertible notes, recent FDA complete response letters for ONS-5010/LYTENAVA, and regulatory and financing risks described under "Risk Factors."
Outlook Therapeutics, Inc. is offering shares of common stock, pre-funded warrants and common warrants pursuant to a preliminary prospectus supplement to a registration statement (Reg. No. 333-278340). The offering pairs each share (or pre-funded warrant) with a common warrant exercisable for one share and expiring five years after issuance.
The company reports 84,614,219 shares of common stock outstanding as of March 20, 2026 and a last reported sale price of $0.35 per share on that date. As of December 31, 2025, cash and cash equivalents were $8.7 million. Debt highlights: a $33.1 million promissory note issued March 13, 2025 (the March 2025 Note) convertible into common stock, of which Avondale converted $6.9 million into shares at a weighted average price of $0.46 as of March 20, 2026; an agreement to issue an $18.36 million note on March 16, 2026 to partially repay the March 2025 Note, leaving approximately $9.7 million remaining under the March 2025 Note as of March 20, 2026.
The company discloses three FDA Complete Response Letters regarding its BLA for ONS-5010/LYTENAVA and ongoing regulatory engagement; the FDA has indicated confirmatory evidence of efficacy is required. Outlook has EU and UK marketing authorizations and launched in initial markets. The prospectus warns of substantial doubt about Outlook’s ability to continue as a going concern and Nasdaq noncompliance with the $1.00 bid-price rule, with a compliance date of August 17, 2026.
Outlook Therapeutics entered a Note Purchase Agreement with Atlas Sciences, issuing an unsecured promissory note with an original principal balance of $18,360,000. The note was sold at a discount for $17,000,000, which must be used solely to repay $17,000,000 of an existing convertible note held by Avondale Capital.
The new note bears interest at the prime rate plus 3%, with a floor of 9.5%, matures 15 months after closing, includes a 7.5% exit fee on cash payments, and allows Atlas to redeem up to $3,000,000 per quarter starting six months after closing. After repayment, about $10.8 million remains outstanding on the Avondale note, whose maturity was extended to December 31, 2026.
In updated risk factors, the company reports cash and cash equivalents of $8.7 million as of December 31, 2025 plus $2.4 million from at-the-market sales, and states there is substantial doubt about its ability to continue as a going concern without substantial additional capital. It also highlights repeated FDA Complete Response Letters for ONS-5010/LYTENAVA and its heavy dependence on this single product.
Outlook Therapeutics, Inc. announced that its Board of Directors accepted the resignation of Dr. Julia Haller from the Board, effective March 11, 2026. She had served as a Class director and was a member of the Nominating and Corporate Governance Committee.
The Board resolved to reduce its size to nine directors upon her resignation. According to the company, Dr. Haller’s decision was not the result of any dispute or disagreement regarding the company’s operations, policies, or practices, and the Board expressed appreciation for her service.